StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen KANJINTI (trastuzumab-anns by Quarter

KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M)

QuarterlyAnnual

Amgen KANJINTI (trastuzumab-anns: $11M in Q4 2023, down 15.4% from a year earlier. That is the lowest of the 20 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2023
11
Period ended Dec 31, 2023
Change on a year earlier
-15.4%
13 in Q4 2022
History
20 quarters
Since Q1 2019
Sources
20
Documents cited below

Where the Q4 2023 figure comes from

“|| KANJINTI ® | 31 | 11 | 42 | 63 | (33%)”

Source: Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M)Year on yearSource
Q4 2023Dec 31, 202311-15.4%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 202313-7.1%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 202312-25.0%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 202314-12.5%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202213-7.1%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 202214-41.7%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 202216-33.3%Form 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 202216-48.4%Form 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q4 2021Dec 31, 202114-51.7%Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021Sep 30, 202124+33.3%Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 202124+9.1%Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021Mar 31, 202131+34.8%Form 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗
Q4 2020Dec 31, 202029+20.8%Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
Q3 2020Sep 30, 202018-40.0%Form 8-K (amgn-2020930xq3ex991.htm, filed 2020-10-28) ↗
Q2 2020Jun 30, 202022-26.7%Form 8-K (amgn-2020630xq1ex991.htm, filed 2020-07-28) ↗
Q1 2020Mar 31, 202023-4.2%Form 8-K (amgn-2020331xq1ex991.htm, filed 2020-04-30) ↗

Cite this data

StockData. (2026). Amgen KANJINTI (trastuzumab-anns ($M), quarterly Q1 2019–Q4 2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-kanjinti-row

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.